IDegLira is a combination of Tresiba (insulin degludec), a once-daily basal insulin analogue with an ultra-long duration…
Injectable Medication
Sanofi’s Lyxumia Approved for Type 2 Diabetes Treatment in Japan
Japan's Ministry of Health, Labor and Welfare (MHLW) approved the manufacturing and distribution of Sanofi's new type 2 …
Biodel to Produce Glucagon Rescue Product
Biodel has announced plans to submit a New Drug Application (NDA) to the FDA in 2015 for a novel glucagon rescue device …
FDA To Re-Evaluate Type 2 Diabetes Drugs Following New Research
The FDA is evaluating unpublished new findings by a group of academic researchers that suggest an increased risk of panc…
FDA to Review NDA for Lixisenatide, Sanofi’s New Type 2 Diabetes Therapy
The FDA has accepted Sanofi's New Drug Application (NDA) for lixisenatide, the first once-daily prandial GLP-1 receptor …
Lyxumia, Sanofi’s Type 2 Diabetes Treatment, Approved in EU
The European Commission has granted Marketing Authorisation in Europe for Sanofi's new type 2 diabetes treatment, Lyxum…
Zealand Pharma Begins Phase 1 Study of Type 2 Diabetes Drug
Zealand Pharma, a Danish biotechnology company dedicated to the discovery and development of innovative peptide drugs, a…
FDA approves Lucentis for Diabetic Macular Edema
The U.S. FDA has approved Roche's Lucentis (ranibizumab injection) for the treatment of diabetic macular edema (DME), a …
Novo Nordisk to Begin Phase 3 Development of Semaglutide for Type 2 Diabetes
Semaglutide successfully completed phase 2 development in 2010. At that time, it was decided to compare semaglutide with…
New Observational Data Shows Patients Prefer Victoza
New data from observational studies in the UK shows that patients with type 2 diabetes experience greater reduction of H…
